BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
Ulrike Rauh(Centro de Pesquisas Oncológicas), Todd R. Golub(Broad Institute), Katrin Nowak‐Reppel(Nuvisan (Germany)), Georgios Kosmidis(Netherlands Consortium for Healthy Ageing), Matthias Ocker(Unknown), Karl Ziegelbauer(Almirall (Spain)), Jennifer A. Roth(Broad Institute), Virendar K. Kaushik(Broad Institute), Franziska Siegel(University of Bonn), Brian K. Hubbard(Broad Institute), James M. McFarland(Broad Institute), Sabine Pilari, Nicolas D. Werbeck(Bayer (Germany)), Kyle Frankel Davis(McCormick (United States)), Weiqun Zhang(Broad Institute), Kai Thede(Nuvisan (Germany)), Douglas S. Daniels(Broad Institute), Michael H. Serrano‐Wu(Broad Institute), Stefan Kaulfuß(Pfizer (Germany)), G. Poncet-Montange(Broad Institute), Stephan Menz(Bayer (Germany)), Christopher T. Lemke(Broad Institute)
Cited by 28
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k